Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results

PURPOSE: The objectives of the ongoing, Phase 3, open-label extension trial enliGHten are to assess the long-term safety and efficacy of weekly administered long-acting growth hormone lonapegsomatropin in children with growth hormone deficiency. METHODS: Eligible subjects completing a prior Phase 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Maniatis, Aristides K, Casella, Samuel J, Nadgir, Ulhas M, Hofman, Paul L, Saenger, Paul, Chertock, Elena D, Aghajanova, Elena M, Korpal-Szczyrska, Maria, Vlachopapadopoulou, Elpis, Malievskiy, Oleg, Chaychenko, Tetyana, Cappa, Marco, Song, Wenjie, Mao, Meng, Mygind, Per Holse, Smith, Alden R, Chessler, Steven D, Komirenko, Allison S, Beckert, Michael, Shu, Aimee D, Thornton, Paul S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Online Only Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202697/
https://www.ncbi.nlm.nih.gov/pubmed/35428884
http://dx.doi.org/10.1210/clinem/dgac217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202697/
https://www.ncbi.nlm.nih.gov/pubmed/35428884
http://dx.doi.org/10.1210/clinem/dgac217

Ejemplares similares